U.S. biotech firm Illumina has enlisted Slaughter and May and Covington & Burling in a legal action against the European Commission over its probe into the group’s $8 billion acquisition of fellow U.S. cancer screening business, GRAIL.
Illumina, which specialises in genetic sequencing, filed an action with the General Court of the European Union in Brussels on Thursday seeking to annul the Commission’s review, according to a statement by the San Diego-based company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]